Meloxicam (Metacam)

Meloxicam, widely known by the brand name Metacam, is a nonsteroidal anti-inflammatory drug extensively used in veterinary medicine for the management of pain and inflammation in dogs. As a preferential cyclooxygenase-2 (COX-2) inhibitor, meloxicam provides effective analgesic and anti-inflammatory effects while demonstrating some selectivity for the COX-2 enzyme over COX-1, a characteristic designed to improve tolerability compared to older, non-selective NSAIDs. Originally developed for human use, meloxicam has been adapted and approved specifically for veterinary applications, making it one of the most commonly prescribed pain medications in canine medicine worldwide. Its established efficacy and long track record have made Metacam a cornerstone of osteoarthritis management in dogs.

The mechanism of action of meloxicam centers on the inhibition of cyclooxygenase enzymes, which are responsible for converting arachidonic acid into prostaglandins. Prostaglandins are signaling molecules that play crucial roles in inflammation, pain perception, fever, and various protective physiological functions. The COX-2 isoform is primarily induced during inflammatory states and is largely responsible for producing the prostaglandins associated with pain and inflammation. By preferentially inhibiting COX-2 while having less effect on COX-1, which produces prostaglandins important for gastrointestinal mucosal protection and normal platelet function, meloxicam aims to provide therapeutic anti-inflammatory and analgesic effects while potentially reducing some adverse effects associated with complete COX inhibition.

One of the distinguishing features of Metacam for veterinary use is its availability as a palatable oral suspension, which offers significant advantages for dosing precision, particularly in smaller dogs. The liquid formulation comes with a calibrated dosing syringe that allows owners to measure exact amounts based on their dog's weight, eliminating the need for tablet splitting and ensuring accurate dosing across the entire size range of canine patients. Meloxicam is also available in tablet form and as an injectable solution for veterinary administration. The medication is typically given once daily after an initial loading dose, with the oral suspension or tablets used for ongoing therapy and the injectable form often employed for postoperative pain management in clinical settings.

While meloxicam has a well-established safety profile when used appropriately, veterinary supervision remains essential for safe and effective treatment. All NSAIDs carry inherent risks, particularly related to gastrointestinal, renal, and hepatic function, and individual patients may vary considerably in their tolerance and response to therapy. Pre-treatment evaluation, including blood work to assess organ function, helps identify patients at higher risk for adverse effects. Ongoing monitoring during treatment allows for early detection of any problems, and owner education about potential side effects ensures that concerning signs are recognized and reported promptly. The significant size variation among dogs, from two-pound Chihuahuas to two-hundred-pound Mastiffs, makes accurate weight-based dosing critical, and veterinary guidance is essential for determining appropriate treatment regimens.

The primary FDA-approved indication for meloxicam in dogs is the control of pain and inflammation associated with osteoarthritis, one of the most common chronic conditions affecting canine patients. Osteoarthritis is a degenerative joint disease characterized by progressive deterioration of articular cartilage, abnormal bone remodeling, inflammation of the joint capsule, and associated soft tissue changes. This condition can affect any joint but most frequently impacts the hips, stifles (knees), elbows, and spine in dogs. The resulting pain, stiffness, and decreased mobility significantly impact quality of life, making effective management essential. Meloxicam addresses both the inflammatory component and the pain associated with osteoarthritis, helping affected dogs maintain mobility and comfort.

Meloxicam is also approved for use as a single injection for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy (spay), and castration in dogs. Surgical procedures inevitably cause tissue trauma that triggers inflammatory responses and pain, which can impede recovery and cause significant patient distress. When administered preoperatively or at the time of surgery, meloxicam provides anti-inflammatory and analgesic effects during the critical immediate postoperative period. For extended postoperative pain management, oral meloxicam may be continued following the initial injection, though careful attention to appropriate dosing and duration is required.

Veterinarians frequently prescribe meloxicam for various off-label applications where its anti-inflammatory and analgesic properties prove beneficial. Dogs suffering from intervertebral disc disease may receive meloxicam as part of conservative management protocols, as reducing inflammation around affected spinal structures can help alleviate pain and improve neurological function. Hip dysplasia, elbow dysplasia, and other developmental orthopedic conditions often respond well to meloxicam therapy for chronic pain management. Acute musculoskeletal injuries, including sprains, strains, and soft tissue trauma, are commonly treated with short courses of meloxicam to reduce swelling and pain during healing.

Additional clinical applications of meloxicam in canine medicine include management of pain associated with dental procedures, periodontal disease, and oral surgery. The anti-inflammatory effects can help reduce swelling and discomfort following tooth extractions or other dental interventions. Some veterinary oncologists incorporate meloxicam into treatment protocols for certain cancers, as NSAIDs have demonstrated potential anti-tumor effects and can help manage cancer-associated pain and inflammation. Dogs with chronic inflammatory conditions affecting various body systems may benefit from meloxicam's systemic anti-inflammatory effects, though long-term use requires careful monitoring.

The selection of meloxicam over other available NSAIDs depends on multiple factors that veterinarians weigh for each individual patient. The availability of a liquid formulation makes meloxicam particularly attractive for smaller dogs where precise dosing is critical and tablet sizes may not match dosing requirements. The once-daily dosing schedule simplifies owner compliance with treatment regimens. For dogs requiring long-term pain management, meloxicam's extensive safety data from years of clinical use provides confidence for extended therapy when appropriately monitored. Cost considerations, individual patient response to previous treatments, and specific clinical circumstances all influence the decision to prescribe meloxicam as the analgesic of choice.

The dosing of meloxicam in dogs requires careful veterinary calculation based on the individual patient's accurate body weight, as appropriate dosing is fundamental to achieving therapeutic benefit while minimizing adverse effect risk. Veterinarians determine the specific dose after examining the patient, reviewing their complete medical history, and assessing any concurrent health conditions that might influence drug metabolism or increase susceptibility to side effects. Dog owners should never attempt to calculate doses independently or use human meloxicam products, which have different concentrations and formulations than veterinary preparations. The enormous size range in dogs makes weight-based dosing particularly critical, requiring precise measurements that only calibrated veterinary formulations can provide.

For osteoarthritis management in dogs, the typical dosing protocol involves an initial loading dose of 0.2 mg/kg (approximately 0.09 mg/lb) on the first day of treatment, followed by a maintenance dose of 0.1 mg/kg (approximately 0.045 mg/lb) once daily thereafter. This loading dose helps establish therapeutic drug levels more rapidly, providing faster onset of pain relief. The Metacam oral suspension comes with a calibrated dosing syringe marked with weight increments, allowing owners to draw up the precise amount needed for their dog's weight without complex calculations. For the injectable formulation used in surgical settings, the standard dose is 0.2 mg/kg administered subcutaneously as a single injection.

Treatment duration with meloxicam varies considerably based on the underlying condition and individual patient factors. Dogs with osteoarthritis may require long-term or lifelong therapy to maintain comfort and mobility, with the goal of using the lowest effective dose for the duration necessary. Periodic veterinary reassessment allows for evaluation of treatment efficacy, monitoring for adverse effects, and adjustment of the treatment plan as needed. For acute conditions such as postoperative pain or soft tissue injuries, treatment courses are typically much shorter, usually lasting only until the acute inflammatory phase has resolved, which may be several days to a couple of weeks depending on the severity of the condition.

Meloxicam should be administered orally, and the oral suspension should be given according to the manufacturer's instructions for proper measurement and administration. The medication can be given with or without food, though many veterinarians recommend administration with food to help minimize potential gastrointestinal irritation. The oral suspension can be placed directly in the dog's mouth using the provided dosing syringe or mixed with a small amount of food. The liquid formulation has a honey flavor that most dogs accept readily. Tablets, when used, should not be crushed unless specifically directed, and accurate dosing requires using the appropriate tablet strength for the dog's weight.

If a dose of meloxicam is missed, it should be administered as soon as the owner remembers, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped entirely, and the regular dosing schedule should resume. Owners should never administer double doses to compensate for missed medication, as this significantly increases the risk of adverse effects, particularly gastrointestinal and renal complications. For dogs on long-term meloxicam therapy, establishing a consistent daily routine for medication administration helps minimize the likelihood of missed doses. Associating the medication with a regular activity, such as breakfast, helps maintain compliance.

Completing the prescribed course of treatment is important even if the dog appears to feel better before the medication is finished, particularly for acute conditions where underlying inflammation may persist despite symptomatic improvement. However, owners should remain vigilant for any signs of adverse effects throughout treatment and should contact their veterinarian if concerns arise rather than automatically continuing medication. For chronic conditions like osteoarthritis, ongoing therapy requires regular follow-up appointments to assess treatment response, monitor for potential complications through physical examination and laboratory testing, and make informed decisions about continuing, adjusting, or discontinuing therapy based on the evolving clinical picture.

Meloxicam is generally well-tolerated by most dogs when administered at appropriate doses under veterinary supervision, and the majority of patients complete treatment without experiencing notable adverse effects. However, like all NSAIDs, meloxicam carries inherent risks that owners should understand and monitor for throughout the treatment period. The preferential COX-2 selectivity of meloxicam was designed to reduce some side effects compared to older, non-selective NSAIDs, but all medications in this class share similar safety considerations. Awareness of potential adverse reactions enables owners to provide appropriate care and seek veterinary attention when necessary.

The most commonly observed side effects of meloxicam involve the gastrointestinal system. Some dogs may experience decreased appetite, vomiting, diarrhea, or soft stools during treatment. These effects are often mild and self-limiting, resolving on their own or with simple supportive measures such as administering the medication with food. Changes in stool consistency or frequency may occur, and some dogs may show temporary reluctance to eat. While these gastrointestinal effects are usually manageable, persistent or worsening symptoms warrant veterinary consultation to determine whether treatment should be modified or additional interventions are needed.

More serious gastrointestinal complications, though less common, include gastric ulceration and gastrointestinal bleeding. NSAIDs can compromise the protective mucus lining of the stomach and intestines, potentially leading to erosions, ulcers, and bleeding. Signs of these complications include bloody or dark tarry stools (indicating digested blood), vomiting blood or material resembling coffee grounds, abdominal pain, sudden severe loss of appetite, or weakness and pale gums suggesting blood loss. These symptoms require immediate veterinary attention, as gastrointestinal ulceration can progress rapidly and become life-threatening without prompt treatment. Dogs with pre-existing GI issues or those receiving concurrent medications that affect the digestive tract may be at increased risk.

Meloxicam, like other NSAIDs, has the potential to affect kidney and liver function, particularly with prolonged use or in predisposed individuals. The kidneys rely on prostaglandins to maintain adequate blood flow, especially during times of physiological stress, and NSAID-induced reduction in prostaglandin synthesis can impair renal function. Signs of kidney problems may include increased thirst, changes in urination patterns (increased or decreased frequency), changes in urine color or concentration, or loss of appetite. Hepatic effects might manifest as jaundice (yellowing of the gums, whites of the eyes, or skin), lethargy, vomiting, or dark urine. Pre-existing kidney or liver disease significantly increases the risk of these complications, emphasizing the importance of pre-treatment screening and ongoing monitoring.

Rare but serious adverse effects associated with meloxicam include allergic reactions and idiosyncratic responses. Signs of allergic reaction may include facial swelling, hives, difficulty breathing, or sudden collapse. Behavioral changes, neurological signs, or skin reactions have been reported in uncommon cases. Some dogs may experience effects on blood clotting or develop anemia. While these reactions are infrequent, their potential severity means that any unusual symptoms during meloxicam treatment should be reported to the veterinarian promptly. If a severe reaction is suspected, treatment should be discontinued immediately and emergency veterinary care sought. Overall, the benefits of meloxicam therapy typically outweigh the risks for appropriately selected patients, but ongoing vigilance ensures patient safety throughout the treatment period.

Meloxicam should not be administered to dogs with known hypersensitivity or allergy to meloxicam or other NSAIDs. Dogs that have previously experienced adverse reactions to any NSAID, including symptoms such as facial swelling, hives, difficulty breathing, gastrointestinal bleeding, or severe digestive upset, should not receive meloxicam without careful consideration and close veterinary supervision. Cross-reactivity between different NSAIDs can occur, meaning a dog that reacted poorly to one medication in this class may also react to others. Owners must inform their veterinarian of any previous adverse drug reactions their dog has experienced, including reactions to over-the-counter human medications containing NSAIDs such as ibuprofen, naproxen, or aspirin.

Dogs with pre-existing kidney disease or compromised renal function should generally not receive meloxicam, as NSAIDs can further impair kidney function through their effects on renal blood flow and prostaglandin-mediated kidney protection. The kidneys rely on certain prostaglandins to maintain adequate perfusion and filtration capacity, particularly during periods of stress, dehydration, or reduced cardiac output. By inhibiting prostaglandin production, meloxicam can reduce renal blood flow and potentially precipitate acute kidney injury or accelerate progression of existing chronic kidney disease. Dehydrated dogs or those with any condition that compromises renal perfusion are similarly at increased risk and should not receive meloxicam until their hydration status has been corrected and stabilized.

Liver disease represents another significant contraindication for meloxicam use in dogs. The liver is the primary organ responsible for metabolizing meloxicam, and dogs with hepatic impairment may not process the drug efficiently, leading to accumulation and increased risk of toxicity. Additionally, NSAIDs can occasionally cause hepatotoxicity even in dogs with previously normal liver function, and this risk may be elevated in patients with underlying hepatic disease. Pre-treatment liver function testing through blood work helps identify dogs at higher risk, and the medication should be avoided in patients with active liver disease, significantly elevated liver enzymes, or clinical signs of hepatic dysfunction.

Meloxicam should not be used in dogs with active gastrointestinal ulceration or bleeding, as the drug can exacerbate these conditions. Dogs with a history of GI ulceration should be carefully evaluated, and alternative pain management strategies may be more appropriate for these patients. Bleeding disorders or concurrent anticoagulant therapy require careful consideration, as NSAIDs can affect platelet function and blood clotting. Pregnant and nursing dogs should not receive meloxicam due to potential effects on fetal development, parturition, and nursing offspring. Very young puppies and dogs that are severely debilitated or in shock are not appropriate candidates for NSAID therapy. Complete disclosure of a dog's medical history to the veterinarian ensures that contraindications are properly identified and safer alternatives are selected when necessary.

Informing your veterinarian about all medications, supplements, and products your dog receives is essential before starting meloxicam therapy, as numerous potential drug interactions can affect treatment safety and efficacy. NSAIDs interact with many other medication classes, and some combinations can significantly increase the risk of serious adverse effects or alter the effectiveness of one or both drugs. Even seemingly innocuous over-the-counter products, dietary supplements, or herbal remedies can interact with meloxicam in clinically meaningful ways. A comprehensive medication and supplement history enables the veterinarian to identify potential interactions and develop a safe treatment plan.

The concurrent use of meloxicam with other NSAIDs, including aspirin, is strongly contraindicated due to the dramatically increased risk of gastrointestinal ulceration, bleeding, and kidney damage when these drugs are combined. This prohibition applies to all prescription veterinary NSAIDs such as carprofen, firocoxib, deracoxib, and robenacoxib, as well as human over-the-counter NSAIDs like ibuprofen or naproxen. Even low-dose aspirin therapy, sometimes administered for antiplatelet effects, should not be combined with meloxicam without specific veterinary guidance and careful consideration of the compounded risks. When switching between different NSAIDs, an appropriate washout period of at least five to seven days should be observed to allow the previous medication to clear the system.

Corticosteroids and meloxicam should generally not be used concurrently due to the substantially increased risk of serious gastrointestinal side effects when these drug classes are combined. Both NSAIDs and corticosteroids can independently cause gastric ulceration, and their concurrent use synergistically amplifies this risk. If a dog has been receiving corticosteroid therapy, such as prednisone or dexamethasone, an appropriate washout period is necessary before starting meloxicam. The required duration depends on the specific corticosteroid used, its dose, and the length of therapy, and should be determined by the prescribing veterinarian. In rare circumstances where both drug classes are deemed medically necessary, gastroprotective therapy and intensive monitoring may be implemented.

Meloxicam may interact with various other medications commonly used in veterinary medicine. The drug can potentially affect the activity of anticoagulants such as warfarin, increasing bleeding risk. Concurrent use with ACE inhibitors, angiotensin receptor blockers, or diuretics, often prescribed for heart disease or hypertension, requires careful monitoring as NSAIDs can reduce the effectiveness of these cardiovascular medications and may contribute to kidney stress. Some antibiotics, particularly aminoglycosides like gentamicin, pose increased nephrotoxicity risk when combined with NSAIDs. Highly protein-bound drugs may compete with meloxicam for protein binding sites, potentially altering the effective levels of either medication. Dogs receiving digoxin, methotrexate, ciclosporin, or phenobarbital along with meloxicam may require dose adjustments or enhanced monitoring.

Dietary supplements and alternative therapies used in dogs can also interact with meloxicam. Fish oil supplements, while often beneficial for joint health and inflammation, have mild anticoagulant properties that may be additive with NSAID effects on platelet function. Glucosamine and chondroitin supplements commonly used for osteoarthritis do not typically interact adversely with meloxicam and are often used concurrently. However, herbal supplements with potential anti-inflammatory or blood-thinning properties warrant discussion with the veterinarian before combining with meloxicam therapy. Regular communication about any changes to the dog's medication or supplement regimen throughout treatment helps ensure continued safety and efficacy.

General precautions for meloxicam use begin with ensuring proper patient selection and appropriate dosing based on accurate body weight measurement. Dogs should be weighed on a reliable scale before each prescription or refill to account for weight changes that might affect dosing requirements. The oral suspension should be measured using only the calibrated dosing syringe provided with the medication, not household spoons or other measuring devices. Owners must administer exactly the amount prescribed by the veterinarian and should never adjust doses or share medication between pets without explicit veterinary guidance. Following the prescribed dosing schedule closely helps ensure optimal treatment outcomes while minimizing risks.

While meloxicam does not carry the same specific concerns regarding the MDR1 (ABCB1) gene mutation as some other veterinary medications, responsible medication use includes awareness of breed-related drug sensitivities. Herding breeds such as Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and their crosses have higher prevalence of the MDR1 mutation, which affects how certain drugs are metabolized and eliminated. Although meloxicam is not among the medications most significantly impacted by this mutation, owners of herding breed dogs should inform their veterinarian of their dog's breed heritage and report any unusual reactions promptly. Genetic testing can definitively determine MDR1 status and help guide overall medication management.

Environmental and handling precautions help ensure safe use of meloxicam in multi-pet and multi-person households. The honey-flavored oral suspension may be attractive to pets, making secure storage essential to prevent accidental ingestion. Medication should be stored out of reach of all household members, including other animals. In multi-pet households, meloxicam should only be given to the prescribed dog under direct supervision. Child-resistant caps provide some protection, but medications should be stored in locations inaccessible to children regardless. Owners handling the medication do not require special protective measures beyond normal hygiene practices, though the oral suspension should be administered carefully to avoid spillage.

Monitoring requirements during meloxicam therapy include both owner observation at home and veterinary assessment through examinations and laboratory testing. At home, owners should watch for any changes in appetite, water consumption, urination patterns, stool consistency or color, energy level, or behavior. Signs of gastrointestinal distress such as vomiting, diarrhea, or reluctance to eat should be noted and reported. Veterinary monitoring typically includes baseline blood work before starting treatment to assess kidney and liver function, followed by periodic rechecks during long-term therapy. The frequency of monitoring depends on patient risk factors, concurrent medications, and duration of therapy. Any abnormalities identified during monitoring allow for early intervention.

Special patient populations require additional consideration when meloxicam is prescribed. Geriatric dogs often have age-related decline in organ function that affects drug metabolism and increases susceptibility to adverse effects, warranting more conservative dosing and closer monitoring. Very young puppies should not receive meloxicam, as safety in this population has not been established. Dogs with concurrent health conditions, particularly those affecting the heart, kidneys, liver, or gastrointestinal tract, require careful benefit-risk assessment before NSAID therapy is initiated. Working dogs, performance dogs, and those engaged in strenuous activity may mask pain symptoms that would normally limit activity, potentially leading to overexertion while on pain medication. Appropriate activity restrictions should be discussed with the veterinarian.

Proper storage of meloxicam maintains medication potency and prevents accidental ingestion by pets or children. Metacam oral suspension should be stored at controlled room temperature, typically between 59 and 77 degrees Fahrenheit (15 to 25 degrees Celsius). The bottle should be kept tightly closed when not in use to prevent evaporation or contamination. Storage areas should be dry and protected from excessive humidity and temperature extremes. Avoid storing the medication in locations subject to significant temperature fluctuations, such as bathrooms, kitchens near stoves, vehicles, or areas with direct sunlight. The injectable formulation may have different storage requirements, which should be confirmed with the dispensing veterinarian.

The oral suspension should be shaken well before each use to ensure uniform distribution of the active ingredient throughout the liquid. After measuring the appropriate dose with the provided calibrated syringe, the syringe should be rinsed with water after each use to prevent buildup of dried medication, which could affect subsequent dose accuracy. The syringe should be allowed to dry before storage. If the suspension appears discolored, contains particles, or has an unusual odor, it should not be used, and the dispensing pharmacy or veterinary clinic should be contacted. The medication should be used within the timeframe specified on the label, as stability may decrease after extended storage.

Secure storage is critically important to prevent accidental ingestion by household pets or children. The honey-flavored oral suspension and any remaining tablets may be attractive to dogs, and cases of dogs accessing and consuming medication have resulted in serious overdose situations. Medication must be stored in locations completely inaccessible to pets, such as high cabinets with secure closures, locked containers, or child-resistant medicine cabinets. Never leave the medication bottle, dosing syringe containing medication, or loose tablets on counters, tables, or other accessible surfaces. Even brief periods of inattention can allow a determined pet to access medication left unattended.

Proper disposal of unused, expired, or unwanted meloxicam protects both household members and the environment. The preferred disposal method is through drug take-back programs offered by many pharmacies, veterinary clinics, and community organizations, which ensure safe and environmentally responsible destruction of medications. If take-back programs are unavailable, the FDA recommends mixing the medication with an undesirable substance such as coffee grounds, dirt, or cat litter, sealing the mixture in a container, and disposing of it in household trash. The oral suspension should be disposed of completely rather than poured down drains, as pharmaceuticals can contaminate water supplies. Remove personal information from labels before discarding empty containers. Expired medications should never be administered to pets, as degradation may affect both safety and efficacy.

Meloxicam is generally well-tolerated across the diverse spectrum of dog breeds when appropriately prescribed and administered according to veterinary guidance. The tremendous variation in canine body size, ranging from tiny toy breeds weighing just a few pounds to giant breeds exceeding 150 pounds, primarily affects dosing calculations rather than fundamental drug safety or efficacy. The availability of meloxicam as an oral suspension with a calibrated dosing syringe makes it particularly well-suited for precise dosing across this entire size range. Veterinarians consider breed-related factors alongside individual patient characteristics when prescribing meloxicam, ensuring optimal treatment for each dog.

Certain breed-specific health predispositions warrant consideration in the context of meloxicam therapy. Breeds with increased prevalence of kidney disease, such as English Cocker Spaniels, Bull Terriers, Shar-Peis, and Cavalier King Charles Spaniels, may require more frequent monitoring of renal function during NSAID therapy. Breeds prone to liver conditions should similarly receive appropriate hepatic monitoring. Breeds predisposed to gastrointestinal problems may face elevated risk of NSAID-related digestive complications and may benefit from gastroprotective strategies or alternative pain management approaches. Breeds with known bleeding tendencies require careful evaluation before initiating NSAID therapy that affects platelet function.

Size considerations play an important role in meloxicam therapy across the breed spectrum. Giant breeds such as Great Danes, Mastiffs, Saint Bernards, Irish Wolfhounds, and Newfoundlands require larger absolute doses, which increases medication costs for long-term therapy. These breeds also tend to develop osteoarthritis and other orthopedic conditions at relatively young ages due to the mechanical stresses associated with their large body mass, potentially requiring years of pain management. Conversely, toy and small breeds such as Chihuahuas, Yorkshire Terriers, Pomeranians, and Maltese benefit significantly from the liquid formulation's ability to provide precise, small-volume doses that would be impossible to achieve with tablets. The calibrated dosing syringe ensures accuracy even for very small dogs.

Age considerations intersect with breed characteristics to influence meloxicam use in important ways. Large and giant breed dogs are often considered senior at earlier chronological ages than small breeds, with some giant breeds entering their geriatric years as early as five to six years of age, while small breeds may not reach senior status until ten or older. This affects both when osteoarthritis management may become necessary and how long treatment may continue over the dog's lifetime. Puppies of all breeds should not receive meloxicam until they have matured sufficiently, though the specific age at which NSAID use becomes appropriate may vary based on breed and individual development. Senior dogs universally require more careful NSAID use due to age-related decline in organ function, but the vigilance required and specific monitoring protocols may differ based on breed-typical health concerns and aging patterns.

Several other veterinary-approved NSAIDs serve as alternatives to meloxicam for managing pain and inflammation in dogs. Carprofen (Rimadyl, Novox) is one of the most widely prescribed canine NSAIDs with an extensive safety record spanning decades of use. Firocoxib (Previcox) and deracoxib (Deramaxx) are COX-2 selective NSAIDs offering once-daily dosing in chewable tablet form. Grapiprant (Galliprant) represents a newer approach, working as a piprant that blocks the EP4 prostaglandin receptor rather than inhibiting COX enzymes. Robenacoxib (Onsior) is approved for short-term use in dogs. The choice among these options depends on individual patient factors, formulation preferences, previous treatment responses, cost considerations, and veterinary assessment of the most appropriate medication for each specific situation.

When NSAIDs are contraindicated or insufficient for pain control, alternative medication classes may be employed. Gabapentin is frequently used for chronic pain management, particularly for conditions with neuropathic components, and can be combined with NSAIDs for multimodal analgesia when appropriate. Amantadine is another adjunctive medication that may enhance pain control. For severe acute pain in clinical settings, injectable opioids such as buprenorphine, hydromorphone, or methadone may be used. Tramadol, though its efficacy in dogs has been questioned by recent research, is still occasionally prescribed. Corticosteroids provide potent anti-inflammatory effects but are generally not combined with NSAIDs and carry significant side effects with long-term use. Bedinvetmab (Librela), a monoclonal antibody targeting nerve growth factor, offers monthly injection-based pain management as an alternative to daily oral medications.

Complementary approaches often support meloxicam therapy for optimal management of painful conditions in dogs. Joint supplements containing glucosamine, chondroitin, and omega-3 fatty acids are commonly recommended alongside NSAIDs for dogs with osteoarthritis. Weight management programs are crucial for reducing mechanical stress on affected joints, potentially allowing for lower NSAID doses or improved treatment response. Physical rehabilitation, including therapeutic exercises, underwater treadmill therapy, and professional manual techniques, can significantly improve mobility and comfort beyond medication alone. Environmental modifications such as orthopedic bedding, ramps or stairs to avoid jumping, raised food bowls, and non-slip floor surfaces support dogs with mobility limitations. Acupuncture and laser therapy are increasingly offered as adjunctive treatments. Any changes to a dog's treatment regimen should be discussed with the prescribing veterinarian to ensure safety, efficacy, and appropriate coordination of care.